论文部分内容阅读
吉非替尼是一种表皮生长因子受体(EGFR)酪氨酸激酶抑制剂,对晚期非小细胞肺癌的治疗在一定范围内有显著的效果,而EGFR突变有望成为吉非替尼敏感性的预测指标。国内外临床和基础研究有助于对吉非替尼的合理使用奠定坚实基础。
Gefitinib is a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), which has a significant effect on the treatment of advanced non-small cell lung cancer in a certain range, and EGFR mutation is expected to become gefitinib sensitivity Predictors. Clinical and basic research at home and abroad will help lay a solid foundation for the rational use of gefitinib.